{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:23:39Z","timestamp":1779920619698,"version":"3.53.1"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,11,11]],"date-time":"2009-11-11T00:00:00Z","timestamp":1257897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:sec><jats:label\/><jats:p> <jats:italic>J. Neurochem.<\/jats:italic> (2010) <jats:bold>112<\/jats:bold>, 843\u2013853.<\/jats:p><\/jats:sec><jats:sec><jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) is characterized by deposition of amyloid\u2010\u03b2 peptide plaque, disrupted amyloid\u2010\u03b2\u2010precursor protein (APP) metabolism, hyperphosphorylation of Tau leading to neurofibrillary tangles and associated neurotoxicity. Moreover, there is synaptic loss in AD, which occurs early and may precede frank amyloidosis. The central cholinergic system is especially vulnerable to the toxic events associated with AD, and reduced acetylcholine levels in specific brain regions is thought to be central to memory deficits in AD. First\u2010generation cholinesterase inhibitors have provided only symptomatic relief to patients with AD by prolonging the action of remaining acetylcholine with little or no change in the course of the disease. Some second\u2010generation cholinesterase inhibitors are multifunctional drugs that may provide more than purely palliative results. To evaluate the effects of the dual acetylcholinesterase and butyrylcholinesterase inhibitor rivastigmine on key aspects of AD, embryonic day 16 rat primary cortical cultures were treated with rivastigmine under media conditions observed to induce time\u2010dependent neurodegeneration. Samples were subjected to western blotting and immunocytochemistry techniques to determine what influence this drug may have on synaptic proteins and neuronal morphology. There was a strong increase in relative cell viability associated with rivastigmine treatment. Significant dose\u2010dependent increases were observed in the levels of synaptic markers synaptosomal\u2010associated protein of 25\u2003kDa (SNAP\u201025) and synaptophysin, as well as the neuron\u2010specific form of enolase. Together with an observed enhancement of neuronal morphology, our results suggest a rivastigmine\u2010mediated novel neuroprotective and\/or neurorestorative effects involving the synapse. Our observations may explain the potential for rivastigmine to alter the course of AD, and warrant further investigations into using butyrylcholinesterase inhibition as a therapeutic strategy for AD, especially with regard to restoration of synaptic function.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1471-4159.2009.06490.x","type":"journal-article","created":{"date-parts":[[2009,11,11]],"date-time":"2009-11-11T15:34:22Z","timestamp":1257953662000},"page":"843-853","source":"Crossref","is-referenced-by-count":39,"title":["A novel effect of rivastigmine on pre\u2010synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer\u2019s disease"],"prefix":"10.1111","volume":"112","author":[{"given":"Jason A.","family":"Bailey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debomoy K.","family":"Lahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"36","article-title":"Image processing with ImageJ","volume":"11","author":"Abramoff M. D.","year":"2004","journal-title":"Biophotonics International"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.22172"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2009.03.001"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1377.001"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2008.05.1394"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490350513"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720507781077313"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000140626.48118.0A"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.4.563"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)91936-X"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270502"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152707783220938"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990152673800"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508575102"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.8.1119"},{"key":"e_1_2_7_18_1","first-page":"249","article-title":"Combination therapy with lecithin and ergoloid mesylates for Alzheimer\u2019s disease","volume":"47","author":"Jenike M. A.","year":"1986","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2006-10108"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.490370612"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(98)00236-8"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450033346957"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02685889"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.112102"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026024607553"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/60.10.929"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199902000-00008"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.18433\/J3MK59"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.1978.tb00545.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1017\/S1461145701002528","article-title":"Brain metabolic and clinical effects of rivastigmine in Alzheimer\u2019s disease","volume":"4","author":"Potkin S. G.","year":"2001","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"e_1_2_7_31_1","unstructured":"RayB. BaileyJ. A. GreigN. H.andLahiriD. K.(2009)Role of rivastigmine in the processing of amyloid beta precursor and synaptic protein: implication in Alzheimer\u2019s disease. Society for Neuroscience Annual Meeting Chicago IL USA. Abstract 235.12."},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2009.08.018"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.136"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.05.005"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0270(00)00228-4"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720506775697142"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1976.tb06472.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)01384-8"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2008.05.031"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410300410"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X80279"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-008-9816-4"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-4159.2009.06490.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-4159.2009.06490.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T14:52:39Z","timestamp":1698936759000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-4159.2009.06490.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1111\/j.1471-4159.2009.06490.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06490.x","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,20]]}}}